Showing results (221-230 of 676) with videos related to

Sort By:
Pageof 68
Hepatology (Baltimore, Md.)|April 14, 2011
Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosisGuanghua Rong, Renqian Zhong, Ana Lleo, et al.
World Journal of Surgery|June 22, 2019
The Application of Indocyanine Green Fluorescence Imaging During Robotic Liver Resection: A Case-Matched StudyMarco Vito Marino, Salomone Di Saverio, Mauro Podda, et al.
World Journal of Surgery|July 9, 2022
Evolving Trends in the Management of Acute Appendicitis During COVID-19 Waves: The ACIE Appy II StudyFrancesco Pata, Marcello Di Martino, Mauro Podda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 2, 2026
Seronegative Autoimmune Hepatitis in Adults Is a Rare Entity Often Obscured by Suboptimal Diagnostic AssessmentFrancesca Colapietro, Charlotte D Slooter, Kalliopi Zachou, et al.
Minerva Gastroenterology|December 10, 2020
Risk stratification in primary sclerosing cholangitisGiacomo Mulinacci, Laura Cristoferi, Andrea Palermo, et al.
Autoimmunity Reviews|July 10, 2016
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approachHani S Mousa, Marco Carbone, Federica Malinverno, et al.
Expert Opinion on Therapeutic Targets|January 18, 2022
An update on novel pharmacological agents for primary sclerosing cholangitisCamilla Gallo, Bright Oworae Howardson, Laura Cristoferi, et al.
Hepatology Communications|September 10, 2019
A National Hospital-Based Study of Hospitalized Patients With Primary Biliary CholangitisValerio Manno, Alessio Gerussi, Marco Carbone, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 12, 2022
Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injuryAna Lleo, Nora Cazzagon, Cristina Rigamonti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 15, 2023
Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trialPietro Invernizzi, Marco Carbone, David Jones, et al.
Pageof 68